Ahmadreza Karimianpour1, Anbukarasi Maran2. 1. Department of Cardiovascular Diseases, Heart & Vascular Institute, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC, 29425, USA. ahmadreza.karimianpour@gmail.com. 2. Department of Cardiovascular Diseases, Heart & Vascular Institute, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC, 29425, USA.
Abstract
PURPOSE OF REVIEW: Coronary artery no-reflow phenomenon is an incidental outcome of percutaneous coronary intervention in patients presenting with acute myocardial infarction. Despite advances in pharmacologic and non-pharmacologic therapies, coronary no-reflow phenomenon occurs more commonly than desired. It often results in poor clinical outcomes and remains as a relevant consideration in the cardiac catheterization laboratory. In this systematic review, we have sought to discuss the topic in detail, and to relay the most recent discoveries and data on management of this condition. RECENT FINDINGS: We discuss several pharmacologic and non-pharmacologic treatments used in the prevention and management of coronary no-reflow and microvascular obstruction. Covered topics include the understanding of pharmacologic mechanisms of current and future agents, and recent discoveries that may result in the development of future treatment options. We conclude that the pathophysiology of coronary no-reflow phenomenon and microvascular obstruction still remains incompletely understood, although several plausible theories have led to the current standard of care for its management. We also conclude that coronary no-reflow phenomenon and microvascular obstruction must be recognized as a multifactorial condition that has certain predispositions and characteristics, therefore its prevention and treatment must begin pre-procedurally and be multi-faceted including certain medications and operator techniques in the cardiac catheterization laboratory.
PURPOSE OF REVIEW: Coronary artery no-reflow phenomenon is an incidental outcome of percutaneous coronary intervention in patients presenting with acute myocardial infarction. Despite advances in pharmacologic and non-pharmacologic therapies, coronary no-reflow phenomenon occurs more commonly than desired. It often results in poor clinical outcomes and remains as a relevant consideration in the cardiac catheterization laboratory. In this systematic review, we have sought to discuss the topic in detail, and to relay the most recent discoveries and data on management of this condition. RECENT FINDINGS: We discuss several pharmacologic and non-pharmacologic treatments used in the prevention and management of coronary no-reflow and microvascular obstruction. Covered topics include the understanding of pharmacologic mechanisms of current and future agents, and recent discoveries that may result in the development of future treatment options. We conclude that the pathophysiology of coronary no-reflow phenomenon and microvascular obstruction still remains incompletely understood, although several plausible theories have led to the current standard of care for its management. We also conclude that coronary no-reflow phenomenon and microvascular obstruction must be recognized as a multifactorial condition that has certain predispositions and characteristics, therefore its prevention and treatment must begin pre-procedurally and be multi-faceted including certain medications and operator techniques in the cardiac catheterization laboratory.
Authors: Michel Ovize; Gary F Baxter; Fabio Di Lisa; Péter Ferdinandy; David Garcia-Dorado; Derek J Hausenloy; Gerd Heusch; Jakob Vinten-Johansen; Derek M Yellon; Rainer Schulz Journal: Cardiovasc Res Date: 2010-05-06 Impact factor: 10.787
Authors: S Sdringola; A Assali; M Ghani; A Yepes; O Rosales; G W Schroth; K Fujise; H V Anderson; R W Smalling Journal: Catheter Cardiovasc Interv Date: 2000-12 Impact factor: 2.692
Authors: Alessandro Durante; Alessandra Laricchia; Giulia Benedetti; Antonio Esposito; Alberto Margonato; Ornella Rimoldi; Francesco De Cobelli; Antonio Colombo; Paolo G Camici Journal: Circ Cardiovasc Imaging Date: 2017-06 Impact factor: 7.792
Authors: C Michael Gibson; M Imran Dotani; Sabina A Murphy; Susan J Marble; Kent W Dauterman; Andrew D Michaels; J Theodore Dodge Journal: Am Heart J Date: 2002-07 Impact factor: 4.749
Authors: Keyur H Parikh; Milan C Chag; Kanan J Shah; Urmil G Shah; Hemang A Baxi; Anish H Chandarana; Ajay M Naik; Joyal N Shah; Hetal D Shah; Ramesh K Goyal Journal: Can J Physiol Pharmacol Date: 2007 Mar-Apr Impact factor: 2.273